Lynn M. Schuchter, M.D. Associate Professor of Medicine University of Pennsylvania Cancer Center

3/8/02


Click here to start


Table of Contents

Lynn M. Schuchter, M.D. Associate Professor of Medicine University of Pennsylvania Cancer Center

Why is there so much controversy regarding the role of IFN in patients with high risk melanoma?

Does IFN improve overall survival in patients with melanoma?

If IFN does improve overall survival in patients with melanoma, is the 10% difference worth the substantial toxicity associated with therapy?

Does IFN improve overall survival?

Does IFN improve overall survival?

IFN and Melanoma

COLON CANCER Adjuvant Therapy of Stage II Disease

Treatment options for a patients with high risk melanoma should remain:

Author: Neuro Oncology